Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kalaris TherapeuticsKLRS -1.02%12 Debt-to-Equity is 0.02 as of Jun. 2026, which is at its 10-year median of 0.02. GuruFocus rates KLRS with a GF Score™ of 12/100. Among 963 Biotechnology companies, Kalaris Therapeutics ranks better than 88.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kalaris Therapeutics's Debt-to-Equity or its related term are showing as below:
KLRS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.2 Med: 0.02 Max: 0.04
Current: 0.02
During the past 4 years, the highest Debt-to-Equity Ratio of Kalaris Therapeutics was 0.04. The lowest was -0.20. And the median was 0.02.
KLRS's Debt-to-Equity is ranked better than 88.06% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs KLRS: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Kalaris Therapeutics Debt-to-Equity Related Terms
Kalaris Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Kalaris Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KLRS vs VRCA, PTHS, RANI: Debt-to-Equity Comparison
For the Biotechnology subindustry, Kalaris Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kalaris Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kalaris Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kalaris Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kalaris Therapeutics (KLRS) has a Debt-to-Equity of 0.02 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kalaris Therapeutics and its competitors. This is near median its historical median of 0.02. According to the industry distribution chart, Kalaris Therapeutics ranks #115 out of 963 companies in the Biotechnology industry, placing it in the top 11.9%.
Is Kalaris Therapeutics' Debt-to-Equity too high?
Kalaris Therapeutics' current Debt-to-Equity of 0.02 is near median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. Kalaris Therapeutics' value of 0.02 is 87.5% below this industry median. Based on the distribution chart, Kalaris Therapeutics ranks #115 out of 963 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' Debt-to-Equity compare to VRCA and PTHS?
According to the Biotechnology industry distribution chart, Kalaris Therapeutics ranks #115 out of 963 companies for Debt-to-Equity. This places Kalaris Therapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Kalaris Therapeutics' value of 0.02 is 87.5% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Kalaris Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kalaris Therapeutics's current Debt-to-Equity of 0.02 is 87.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Kalaris Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kalaris Therapeutics's current Debt-to-Equity is 0.02, which is near median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current Debt-to-Equity of 0.02. The current Debt-to-Equity is 0.02, which is near median its 10-year median of 0.02 and 87.5% below the Biotechnology industry median of 0.16. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current Debt-to-Equity is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score
Get the complete analysis for KLRS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRS has been successfully added to your 
